Table 2. Univariate and multivariate analysis of factors potentially associated with overall survival in patients receiving preoperative chemotherapy before CRCM resection.
|
Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|
| Variables | P-value | HR | P-value | HR |
|
Patient demographics | ||||
| Sex (male/female) | 0.22 | 0.64 | ||
| Age >70 | 0.76 | 1.12 | ||
|
Disease characteristics | ||||
| Synchronous/metachronous metastases | 0.57 | 1.27 | ||
| Primary tumour site: colon/rectum | 0.94 | 1.02 | ||
| Preoperative serum CEA level (μg l−1) | 0.01 | 1.00 | ||
| Preoperative serum CEA change from base line (%) | 0.09 | 0.99 | ||
|
Previous chemotherapy | ||||
| Previous chemotherapy line(s) for metastatic disease | 0.66 | 1.21 | ||
|
Chemotherapy associated with metastases resection | ||||
| Preoperative chemotherapy+anti-angiogenic compound | 0.29 | 0.66 | ||
| Preoperative chemotherapy+anti-EGFR | 0.15 | 0.41 | ||
| Number of preoperative cycles | 0.20 | 1.06 | ||
| Postoperative chemotherapy | 0.63 | 1.83 | ||
| Total number of pre-postoperative cycles | 0.14 | 1.06 | ||
|
Surgery | ||||
| Portal vein embolization | 0.95 | 1.02 | ||
| Resection status R2 | 0.01 | 3.55 | ||
| Resection status R2 vs others | 0.01 | 3.56 | ||
|
Patient-related pathological response | ||||
| Worse TRG among resected metastases | <0.01 | 1.8 | <0.01 | 1.83 |
| Pathological responder status (TRG ⩽3)/non-responder (TRG ⩾4) | 0.02 | 0.42 | ||
|
Imaging tumour response (RECIST) | ||||
| Response (PR or CR)/no response (SD or PD) | 0.92 | 0.96 | ||
Abbreviations: CEA=serum carcinoembryonic antigen; CR=complete response; CRCM=colorectal cancer metastases; EGFR=epidermal growth factor receptor; HR=hazard ratio; PD=progressive disease; PR=partial response; SD=stable disease; TRG=tumour regression grades.